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Context: Surgical treatments of obesity have been shown to induce rapid and prolonged improve-
ments in insulin sensitivity.
Objective: The aim of the study was to investigate the effects of gastric bypass surgery and the
mechanisms that explain the improvement in insulin sensitivity.
Design: We performed a cross-sectional, nonrandomized, controlled study.
Setting: This study was conducted jointly between the Departments of Exercise Science and Phys-
iology at East Carolina University in Greenville, North Carolina.
Subjects: Subjects were recruited into four groups: 1) lean body mass index (BMI)  25 kg/m2;
n  93; 2) weight-matched (BMI  25 to 35 kg/m2; n  310); 3) morbidly obese (BMI  35 kg/m2;
n  43); and 4) postsurgery patients (BMI  30 kg/m2; n  40). Postsurgery patients were weight
stable 1 yr after surgery.
Main Outcome Measures: Whole-body insulin sensitivity, muscle glucose transport, and muscle
insulin signaling were assessed.
Results: Postsurgery subjects had insulin sensitivity index values that were similar to the lean and
higher than morbidly obese and weight-matched control subjects. Glucose transport was higher
in the postsurgery vs.morbidly obese andweight-matched groups. IRS1-pSer312 in the postsurgery
groupwas lower thanmorbidly obese andweight-matchedgroups. InhibitorBwashigher in the
postsurgery vs. the morbidly obese and weight-matched controls, indicating reduced inhibitor of
B kinase  activity.
Conclusions: Insulin sensitivity and glucose transport are greater in the postsurgery patients than
predicted from the weight-matched group, suggesting that improved insulin sensitivity after by-
pass is due to something other than, or in addition to, weight loss. Improved insulin sensitivity is
related to reduced inhibitor of B kinase  activity and enhanced insulin signaling inmuscle. (J Clin
Endocrinol Metab 93: 4656–4663, 2008)
Gastric bypass surgery has been employed as a tool to assistin weight loss in morbidly obese individuals. For over 20
yr, our group has been performing gastric bypass surgery, which
consists of surgical reduction in the size of the stomach and by-
passing a portion of the proximal small intestine. We were the
first to report that gastric bypass surgery results in rapid and
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long-term improvement in insulin sensitivity and an ultimate
reversal of diabetes (1–3). More recently, Dixon et al. (4) ob-
served that laparoscopic adjustable gastric banding resulted in a
higher remission rate of type 2 diabetes compared with conven-
tional medical treatment. Additionally, the reversal of diabetes
by various surgical treatments of obesitywas confirmedbymeta-
analysis, wherein gastric bypass surgery and laparoscopic ad-
justable gastric banding were found to resolve diabetes in approx-
imately 84 and 48% of postsurgery patients, respectively (5).
Although an increase in whole-body insulin sensitivity after
gastric bypass surgery is well established, the mechanisms in-
volved are not fully understood. A potential signaling defect in
the insulin signaling cascade in the muscle of obese and type 2
diabetics may be a cause for reduced insulin sensitivity.We have
shown previously that insulin-stimulated muscle glucose trans-
port is blunted in obese individuals and patients with type 2
diabetes and that insulin-receptor tyrosine kinase activity is di-
minished inobeseanddiabetic skeletalmuscle (6, 7). Serinephos-
phorylation of the insulin receptor substrate (IRS)-1 has been
implicated in inhibiting insulin signal transduction (8, 9), and
although there are many potential serine phosphorylation sites
on IRS-1 (10), the IRS1-Ser312(human)/Ser307(rodent) residue is of
particular interest given its proximity to the phosphotyrosine-
binding domain in IRS-1. The inhibitor of B kinase  (IKK),
a serine kinase, has been suggested as a potential culprit that
results in deficient insulin signal transduction, given that it has
been shown to phosphorylate IRS-1 on Ser312/307 (8, 9, 11, 12).
Moreover, IKK is activated by fatty acid metabolites, such as
diacylglycerol and ceramide (13, 14), which have been shown to
be higher in insulin-resistant states, such as obesity (15).
Obesity is associated with an increased low-grade inflamma-
tory tone, as evidenced by increased levels of proinflammatory
cytokines as well as greater activity of the inflammatory factor,
nuclear factor-B (NF-B) (16–19). NF-B is a nuclear tran-
scription factor that is responsible for the transcription of amul-
titude of cytokines (includingTNF- and IL-1) (20, 21).NF-B
is prevented from reaching the nucleus by an inhibitor, known as
inhibitor B (IB). IB is phosphorylated by IKK, which
results in theubiquitinationanddegradationof IB, andNF-B
is free to migrate into the nucleus. In addition to regulating
NF-B activity, IKK has been shown to directly inhibit insulin
signaling (8, 9, 22). To highlight the role of NF-B pathway
activity in inhibiting insulin signaling, thiazolidinediones, a
known insulin-sensitizing drug, inhibit NF-B activity (22, 23).
Similarly, Yin et al. (24) discovered that themechanismof action
for salicylate in improving insulin sensitivity was its inhibitory
action on IKK.
We are interested in the causes of insulin resistance in muscle
of obese individuals and the mechanisms that improve insulin
resistance after patients have gastric bypass surgery.Thepurpose
of this study was to investigate gastric bypass surgery-induced
increases in insulin sensitivity at thewholebodyandmuscle level.
We also sought to determine a potentialmechanism for the rapid
and sustained improvement in insulin sensitivity as a result of
gastric bypass surgery.
Subjects and Methods
Subjects and study design
To investigate the reversal of insulin resistance after bypass surgery,
three experiments were performed. In the first experiment, whole-body
insulin sensitivity was measured in postsurgery patients and nonsurgical
controls by an iv glucose tolerance test (IVGTT) as outlined below. The
second experiment involved glucose transport measured in rectus abdo-
minis muscle strips from patients having elective surgery. These values
were compared with previous data published for gastric bypass patients
after weight loss (1). The activity of IKK and IRS-1 serine312 phos-
phorylation was assayed in vastus lateralis muscle biopsies of postsur-
gery patients and nonsurgery controls in the third experiment. All sub-
jects were female and considered to be in good health after filling out a
medical history questionnaire. Subjects were informed of potential risks
associated with the study and signed an informed consent document,
which was approved by the East Carolina University Institutional Re-
view Board.
Whole-body insulin sensitivity experiment
The first experiment consisted of 128 female subjects who were di-
vided into four groups. One group consisted exclusively of post-gastric
bypass surgery patients who were weight stable at least 12 months after
surgery (BMI30kg/m2).Theother three groupsof nonsurgery subjects
were divided according to BMI: 1) lean (BMI  25 kg/m2), 2) weight-
matched to postsurgery patients (BMI  25 to 35 kg/m2), and 3) mor-
bidly obese (BMI 35 kg/m2). Asmentioned, this first cohort of subjects
was used to obtain insulin sensitivity data, including fasting insulin and
glucose, as well as insulin sensitivity with a 3-h IVGTT (outlined below).
Muscle glucose transport experiment
In the second experiment, glucose transport was measured in incu-
batedmuscle strips obtained during elective abdominal surgery. Subjects
were recruited into similar BMI groups, namely, lean (BMI 25 kg/m2),
controls weight-matched to postsurgery patients (BMI 25–35 kg/m2),
andmorbidly obese (BMI 35 kg/m2). The data from these groupswere
then compared with data previously reported (1) for five postsurgery
subjects to compare the given groups with postsurgery patients.
IKK activity and IRS1-Ser312 experiment
The third experiment included 36 subjects whowere evenly recruited
into four groups, similar to the BMI groups mentioned above. This co-
hort of subjects had a muscle biopsy (vastus lateralis) that was used to
obtain all muscle protein data.
Roux-en-Y gastric bypass surgery
Thegastricbypass surgerywasperformedasdescribedpreviously (3).
Briefly, Roux-en-Y gastric bypass surgery consists of surgical reduction
in the size of the stomach and bypassing of a portion of the proximal
small intestine (foregut).
Anthropometrics
Body mass was measured to the nearest 0.1 kg on a digital electronic
scale.Heightwasmeasured to the nearest 0.5 cmwith a stadiometer, and
BMI was calculated mass (in kilograms)/height2 (in meters).
IVGTT
Insulin sensitivity was determined by aminimal model analysis using
a 3-h IVGTT (25), as described previously (26). After fasting, samples
were obtained and glucose (50%) was injected into a catheter placed in
an antecubital vein at a dose of 0.3 g/kg body mass. Insulin, at a dose of
0.025 U/kg body mass was injected at min 20. Blood samples were ob-
tained at min 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 19, 22, 25, 30, 40, 50, 60,
70, 80, 90, 100, 120, 140, 160, and 180; the samples were then centri-
fuged; and plasma was transferred and frozen at 80 C for the subse-
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quent determination of insulin and glucose. Insulin was determinedwith
immunoassay (Access Immunoassay System; Beckman Coulter, Fuller-
ton, CA), and glucose was determined with an oxidation reaction (YSI
model 2300Stat Plus;YellowSprings Instruments,YellowSprings,OH).
Insulin sensitivity index (SI) was calculated by using the minimal model
(25); a higher SI indicates greater insulin sensitivity.
Muscle strip incubations
Human rectus abdominis muscle strip preparation and incubation
was performed according to the procedure previously described (6).
Muscle strips were incubated in the presence (100 nM) or absence of
insulin. 2-Deoxy-D-glucose was used at a concentration of 5 mM for 60
min, and glucose transport was measured as described previously (6).
2-1,2-3H(N)Deoxy-D-glucose (30.2 Ci/mmol) was obtained from Du-
Pont NEN Life Science Products (Boston, MA).
Muscle IRS-1, pSer312, and IB protein content
A muscle sample was obtained from the vastus lateralis with the
percutaneousneedle biopsy technique. Biopsy sampleswere immediately
frozen in liquid nitrogen. Frozen muscle samples were homogenized in
ice-cold lysis buffer 50mMHEPES,50mMNapyrophosphate, 100mM
Na fluoride, 10 mM EDTA, 10 mM Na orthovanadate, and protease
and phosphatase (1 and 2) inhibitor cocktails (Sigma, St. Louis, MO),
followed by addition of 1% triton and brief sonication. After centrifu-
gation for 1 h at 45,000 g at 4 C, supernatants were extracted (cytosolic
portion), protein contentwas detected using aBCAprotein assay (Pierce,
Rockford, IL), and individual homogenate volumeswere adjusted so that
precisely 50g of proteinwas loaded into each lane. For IRS1-Ser312 and
total IRS-1 analysis, 200gof homogenateswas subjected to10l IRS-1
monoclonal IPantibody (SantaCruzBiotech, SantaCruz,CA)overnight,
then coupled to protein A Sepharose beads, rotated for 2 h at 4 C (Am-
ersham Biosciences, Uppsala, Sweden), and washed. After addition of
sample buffer, samples were separated by SDS-PAGE using 7.5 or 10%
Tris-HCl gels and then transferred to polyvinylidene difluoride mem-
branes for probing by the following antibodies: rabbit polyclonal IRS-1
and IRS-1 phospho serine312, purchased fromMillipore (Billerica,MA);
and IB antibodies, purchased fromCell Signaling (Beverly,MA).After
incubation with primary antibodies, blots were incubated with appro-
priate horseradish peroxidase-conjugated secondary antibodies. Horse-
radish peroxidase activity was assessed with ECL solution (Thermo Sci-
entific, Rockford, IL) and exposed to film. The image was scanned, and
band densitometrywas assessedwithGel ProAnalyzer software, version
4.2 (Media Cybernetics, Silver Spring, MD). Content of phospho-pro-
teins (using phospho-specific antibodies)was calculated from the density
of the band of the phospho-protein divided by the density of the protein
using the appropriate antibody.
Statistics
All data are shown as mean 	 SE. Comparisons between the groups
with insulin sensitivity, muscle protein levels, and muscle glucose trans-
port rates were made using one-way ANOVA, followed by post hoc
analyses where appropriate. Correlations between variables were deter-
mined by Dunnette T3 post hoc analysis.
Results
Subject characteristics are presented in Table 1. None of the
subjects were taking medications that would interfere with me-
tabolism, all were free from known cardiovascular disease and
diabetes mellitus, and a few were glucose tolerance impaired
(fasting glucose 110 mg/dl; two in the lean group, two in the
obese group, and five in the weight-matched group). The mean
weight of all gastric bypass subjects decreased from136.6	21.5
to 81.9 	 13.2 kg (mean 	 SD; P  0.001), resulting in a mean
weight loss of 54.7 	 18.7 kg. Similarly, BMI fell from 48.6 	
5.7 to 28.8	 4.6 kg/m2 (P 0.001). The BMI of the postsurgery
groups was not significantly different than the weight-matched
control groups.
Fasting glucose, insulin, and insulin resistance (HOMA)
Average plasma glucose concentration for the postsurgery
subjects (76 	 10.2 mg/dl) was lower when compared with all
nonsurgery control subjects (95.3 	 13.8 mg/dl) (Fig. 1A; P 
0.001). There was no significant change in fasting glucose with
increasing BMI in either control or postsurgery groups. Fasting
insulin concentration and BMI were positively correlated (r 
0.598, P  0.001) for all nonsurgery control subjects. In con-
trast, the same correlation in postsurgery subjects revealed no
significant relationship (r 0.304, P 0.169; Fig. 1B). Fasting
glucose and insulin values were used to calculate homeostasis
model assessment (HOMA) values, an index of insulin resis-
tance. HOMA values were significantly related to BMI in the
nonsurgery subjects (P 0.01, r 0.283; Fig. 2A), whereas the
postsurgery patients revealed no significant correlation.
TABLE 1. Characteristics of patients/subjects in the three experiments
Subject characteristics Age (yr) BMI (kg/m2) No. of observations
Experiment 1: Whole-body insulin sensitivity, fasting glucose and insulin
Lean BMI  25 kg/m2 (nonsurgery) 38.9 	 15.0 23.4 	 1.5 33
Weight-matched BMI 25–35 kg/m2 (nonsurgery) 41.8 	 14.1 28.5 	 1.7 50
Morbidly obese BMI  35 kg/m2 (nonsurgery) 40.3 	 16.1 47.7 	 9.5 14
After surgery 43.5 	 9.8 29.4 	 4.9 31
Experiment 2: Muscle glucose transport from rectus abdominis muscle
taken during surgery
Lean (BMI  25 kg/m2) 39.3 	 6.4 22.4 	 2.1 51
Weight-matched (BMI 25–35 kg/m2) 42.6 	 19.0 28.9 	 2.8 251
Morbidly obese (BMI  35 kg/m2) 41.6 	 4.2 46.2 	 4.0 20
Experiment 3: Vastus lateralis muscle biopsy for IRS1-Ser312 and IB
Lean BMI  25 kg/m2 (nonsurgery) 35.1 	 14.4 21.7 	 1.9 9
Weight-matched BMI 25–35 kg/m2 (nonsurgery) 35.5 	 10.1 30.9 	 2.7 9
Morbidly obese BMI  35 kg/m2 (nonsurgery) 32.8 	 13.3 44.6 	 4.2 9
After surgery 40.8 	 8.1 29.9 	 4.1 9
Data represent mean 	 SD. There is no statistical difference in BMI between the weight-matched and postsurgery groups.
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Whole-body insulin sensitivity
The postsurgery group had insulin SI values that were 361%
higher than the morbidly obese and 47% higher than weight-
matched groups (P  0.005 for both; Fig. 2B). The postsurgery
group’s SI levels were not significantly different from the lean
group, despite having a greater BMI.The SI value of themorbidly
obese was 68% lower than the weight-matched controls, sug-
gesting an inverse relationship between whole-body insulin sen-
sitivity and BMI (P  0.05). This is consistent with the positive
correlation between BMI and HOMA from all nonsurgery sub-
jects (Fig. 2A; P  0.01, r  0.283).
Muscle glucose transport
We previously reported that muscle glucose transport was
significantly lower in morbidly obese patients than in lean con-
trols (1, 6). Additionally, in five gastric bypass patients who
subsequently had elective abdominal surgery after weight loss,
muscle glucose transport was not different than that of lean sub-
jects, although the postsurgery group had an average BMI of 31
kg/m2 (1). To determine how postsurgery muscle glucose trans-
port compared with a weight-matched control group, we re-
trieved muscle glucose transport measurements from a database
ofourprevious experiments (Fig. 3A). Previouslypublishedpost-
surgery glucose transport values (1) are shown in Fig. 3A for
comparison. Insulin-stimulated glucose transport values were
lower in the weight-matched group and morbidly obese groups,
compared with the lean control groups (P  0.05). There were
no differences in insulin-stimulated glucose transport between
themorbidly obese andweight-matched groups. This is in agree-
ment with our previous report that muscle glucose transport is
related to BMI up to a BMI of 30 kg/m2, after which there is no
further change (27); i.e. muscle insulin resistance is maximal at
a BMI of 30 kg/m2. Postsurgery glucose transport values were
similar to the lean group and greater than morbidly obese and
weight-matched subjects.
We previously reported that insulin-stimulated glucose trans-
port was depressed in muscle of morbidly obese patients, com-
pared with lean controls (6). With the larger number of obser-
vations in the present data set, we extend this observation by
reporting that basal glucose transport (in the absence of insulin) is
also lower inmuscle of morbidly obese patients. Also, a significant
positive relationship was found between the rates of basal and in-
sulin-stimulated glucose transport (P 0.001, r 0.726; Fig. 3B).
This suggests that the factors that regulate basal glucosemight also
FIG. 2. Whole-body insulin sensitivity determined by HOMA correlated with BMI
(A) and IVGTT for four BMI groups (B). The data for the HOMA and insulin
sensitivity analysis were taken from experiment 1 (Table 1). A, The comparison of
HOMA values for nonsurgery control subjects (black circles) and postsurgery
patients (white triangles). A positive and significant correlation between HOMA
and BMI was found (P  0.01, r  0.283) for the nonsurgery subjects. The same
correlation in postsurgery subjects revealed no significant relationship (P 
0.083, r  0.446). B, The difference in whole-body insulin sensitivity between
BMI groups. *, The postsurgery and lean groups are statistically higher (P 
0.005) than the morbidly obese and weight-matched groups. †, P  0.05 for the
comparison between the morbidly obese and all other groups. Data are
presented as mean 	 SD.
FIG. 1. The correlations between BMI and glucose (A) and insulin (B) for
nonsurgery control subjects (black circles) and postsurgery patients (white
triangles). The data are from experiment 1 patients (Table 1). A, The comparison
of fasting glucose values between nonsurgery control subjects (n  97) and
postsurgery subjects (n  31). B, Fasting insulin values between nonsurgery
subjects and postsurgery subjects. A positive and significant correlation was
found (P  0.001, r  0.598) for the nonsurgery subjects. The same
correlation in postsurgery subjects revealed no significant relationship (P 
0.169, r  0.304).
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be those that regulate the rate in the presence of insulin. This was
unexpected because we had predicted that insulin resistance might
only have an effect on insulin-stimulated glucose transport.
Insulin sensitivity and IRS1-Ser312
Inasmuch as serine312 phosphorylation of the IRS-1 protein
hasbeen implicated in inhibiting insulin signaling, thisparameter
was investigated in vastus lateralis muscle biopsies of lean,
weight-matched, morbidly obese, and postsurgery subjects
(group 3 in Table 1). Ser312 phosphorylation of IRS-1 was sig-
nificantly greater in themorbidlyobeseandweight-matched sub-
jectsvs. the leanandpostsurgery subjects (P0.05). IRS1-Ser312
phosphorylation followed a similar pattern to the insulin-stim-
ulatedglucose transport data. Inparticular, IRS1-pSer312didnot
differ between the morbidly obese and weight-matched groups
(Fig. 4A). Moreover, IRS1-Ser312 phosphorylation in postsur-
gery subjects was significantly reduced by 47% compared with
morbidly obese (P  0.04) and tended to be lower when com-
pared with the weight-matched subjects (P  0.057).
FIG. 4. Muscle levels of IRS1-phospho-Ser312 (A) and IB (B), and the correlation
between IRS1-pSer312 and IB (C). Nonsurgery control subjects and postsurgery
patients were from experiment 3 (Table 1). A, Western blot analysis of serine312
phosphorylation of IRS1. *, P 0.05 for the comparison between the lean group
and the morbidly obese and weight-matched. †, P 0.05 for the comparison
between the postsurgery and the morbidly obese groups. The postsurgery group
tended to have a lower level compared with the weight-matched group (P 0.057).
B, Western blot analysis of IB in skeletal muscle between groups. *, P 0.05 for
the observation that the lean and postsurgery groups were statistically higher than
the morbidly obese and weight-matched groups. IB levels were similar between
postsurgery subjects and lean subjects. C, The correlation between IB and IRS1-
phospho-Ser312 levels between nonsurgery and postsurgery subjects (P 0.003, R
0.47). Data are presented as mean	 SD.
FIG. 3. 2-Deoxy-D-glucose uptake in incubated muscle strips in the presence (100
nM) or absence of insulin (A) and the correlation between basal and insulin-
stimulated glucose transport (B). The data were obtained from subjects in
experiment 2 (Table 1). A, A comparison of basal (empty bars) and insulin-
stimulated (filled bars) glucose transport. *, Insulin-stimulated glucose transport
in the morbidly obese and weight-matched groups was statistically lower (P 
0.05) than the lean and postsurgery groups. †, Basal glucose transport in the
morbidly obese and weight-matched groups was statistically lower (P  0.05)
than the lean and postsurgery groups. Basal and insulin-stimulated glucose
transport in muscle from morbidly obese subjects did not differ from the weight-
matched subjects. B, The correlation between basal and insulin-stimulated
glucose transport revealed a highly significant relationship (P  0.001; r 0.726).
Data are presented as mean 	 SD.
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IB and IRS1-Ser312
Due to the implicated role of IKK as a serine kinase of IRS1-
Ser312, muscle levels of IB, a substrate of IKK that is rapidly
ubiquitinated and degraded upon phosphorylation, were mea-
sured in an effort to determine IKK activity (28). Greater IKK
activitywould be evident in reduced levels of IB. Similar to our
observations with IRS1-phospho-Ser312 and insulin-stimulated
glucose uptake in muscle, IB levels in the postsurgery subjects
were similar to lean subjects and were significantly elevated by
44% compared with the morbidly obese (P  0.05) and 47%
compared with the weight-matched controls (P  0.05), which
demonstrated increased IKK activity in the weight-matched
and morbidly obese compared with the lean and post-bypass
subjects (Fig. 4B). With correlational analysis, we discovered a
highly significant inverse relationship between IB and phos-
pho-Ser312 levels (P  0.003, r  0.47; Fig. 4C).
Discussion
The primary effect of gastric bypass surgery in the obese is sig-
nificantweight loss, but an important side effect of the procedure
is the dramatic and rapid rescuing of insulin sensitivity. We ob-
served lower fasting glucose and insulin values from the post-
surgerygroupcomparedwithall other subjects. Furthermore,we
found that whole-body insulin sensitivity, as measured by
IVGTT, is significantly greater in the postsurgery subjects com-
pared with BMI-matched control subjects. Additionally, despite
having a significantly higher BMI than the lean subjects, post-
surgery subjects enjoy comparable SI values.
We have previously shown that muscle insulin resistance in
obese individuals is related to depressed insulin signal transduction
(7). Because phosphorylation of the IRS1-Ser312(human)/307(rodent)
residue has been implicated in attenuating insulin signal trans-
duction, we measured IRS1-pSer312 and IB protein levels, as
a surrogate for IKK activity, and found that both IB and
IRS1-phospho-Ser312 protein levels in skeletalmuscle frompost-
surgery patients were similar to that seen in muscle from lean
subjects despite the postsurgery group having a significantly
higher BMI (Fig. 4, A and B). TheNF-B pathway has garnished
a great deal of attention recently in regards to its novel effects on
metabolic function and substrate utilization. In particular, IKK
has been studied in a variety of cells, including endothelial, he-
patic, and skeletal muscle. Research into the role of the NF-B
pathway in endothelial cells has been conducted due, in part, to
the pathological consequences of inflammation in the vascular
system (29–32). Recent work by Wu et al. (33) determined that
activation of IKK by TNF- is suppressed by adiponectin. This
is particularly interesting due to the ability of adiponectin to
improve insulin sensitivity (34). Furthermore, studying the role
ofNF-Bpathwayproteins in the liver,Cai et al. (8) revealed that
diet-induced obesity in mice led to increased NF-B pathway
signaling in the liver. Mice with a liver-specific constitutively
active IKK transgene suffered from systemic insulin resistance,
and further analysis revealed a dose-dependent relationship be-
tween NF-B activity in the liver and the onset of system insulin
resistance. Moreover, in human hepatocytes, Gao et al. (35)
treated cells with TNF- and found increased IRS-1 phosphor-
ylation at Ser312. This IRS1-Ser312 phosphorylation correlated
with the disappearance of IB, which represents increased
IKK activity.
Because skeletal muscle is the main depot for insulin-stimu-
lated glucose uptake, studying the effects of IKK on insulin
signaling in this tissue is worthwhile. A study by de Alvaro et al.
(28) reported that IKK activation in rat skeletal muscle cell
culture resulted in a significant increase in IRS1-Ser307 phos-
phorylation. They also explored the role of a pharmacological
IKK inhibitor, salicylate, in preventing IKK-induced insulin
resistance. Targeted disruption of the Ikk locus in mice results
in lower fasting glucose and insulin concentrations, as well as
preventing insulin resistance from a high-fat diet. Similar results
have been reported with salicylate treatment (9). Additionally,
Kim et al. (12) employed lipid infusions in rodents to cause acute
insulin resistance. They observed that this effect was attenuated
with pretreatment with salicylates. Furthermore, lipid infusions
performed in Ikkb heterozygous knockout mice revealed im-
provements in insulin sensitivity during hyperinsulinemic-eugly-
cemic clamps when compared with controls.
IKK activation, and subsequent IRS1-Ser312 phosphoryla-
tion, has been shown to be a result of the accumulation of excess
fatty acids within the muscle that are subsequently partitioned
toward storage or the formation of fatty acid metabolites, re-
sulting in insulin resistance (13–15, 23, 36). We have previously
shown that intramyocellular lipid (IMCL) levels are significantly
reduced after gastric bypass surgery (37).Moreover, Greco et al.
(38) determined that surgery-induced weight loss results in a
greater-than-expected reduction in IMCL when compared with
diet-inducedweight loss alone. IMCLdepletion iscertainlya likely
explanation for the improvements we observed in postsurgery pa-
tients in regards to levels of IB and IRS1-pSer312 due to their role
in mediating lipid-induced insulin resistance, and it may partly ex-
plain the differences in whole-body insulin sensitivity.
Not surprisingly, in control subjects fasting insulin levels and
insulin resistance (HOMA) have positive relationships with
BMI. However, fasting insulin and insulin resistance are not as-
sociated with BMI in the postsurgery subjects. BMI was used as
a global assessment of body fat and weight loss in the current
study. Whereas BMI is not an accurate indicator of body fat in
certain populations with relatively greater muscle mass, given
that all subjects in the current study were sedentary, we feel it is
a legitimate measurement. Moreover, in regards to the weight
loss and reduction in BMI associated with bypass surgery, it has
been shown that the tremendous fat loss associated with gastric
bypass surgery ismostly a result of a reduction in truncal fat (39).
A possible concern may be the possible confounding effect of
a change in food intake as a result of gastric bypass surgery,
whichour grouphaspreviously explored (40).Althoughpatients
experience an acute and meaningful decrease in caloric intake
after surgery that results in significant weight loss, the outcomes
we explored in the current study were measured approximately
12 months after surgery in patients who were weight stable on a
eucaloric diet, which would seemingly negate any dietary effect.
We interpret our data to suggest that the improvement in
insulin sensitivity after gastric bypass is not exclusively due to
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weight loss and may implicate an effect of the surgery itself (2).
A comparison of various surgical interventions lends support for
this hypothesis. Namely, gastric banding surgery restricts food
intake but does not change the channel of food flow. The remis-
sion rate for gastric banding is 48%, whereas that for gastric
bypass is 84% (5). In addition, Dixon et al. (4) reported that the
remission of diabetes was correlated with the degree of weight
loss, which is in contrastwith the datawe present here for gastric
bypass. Moreover, Laferrere et al. (41) compared subjects who
experienced comparable levels of weight loss due to hypocaloric
diet and surgery. Whereas both interventions result in improved
diabetes control, they found that patientswhounderwent bypass
surgery enjoyed a better clinical outcome and no longer required
diabetes medication.
If the improvement in insulin sensitivity after gastric bypass is
not related to weight loss, an attractive alternative hypothesis is
that increased insulin sensitivity and remission of diabetes after
gastric bypass are due to restructuring of the gastrointestinal
tract (2). According to this hypothesis, bypassing a portion of the
duodenum and jejunum causes either: 1) decreased secretion of
adiabetes-inducingpeptide (anti-incretin) fromthe foregut; or 2)
increased secretion of an antidiabetes peptide (incretin) from the
hindgut. This “foregut bypass hypothesis” was first suggested
Pories (2) but has received recent attention byRubino (42), who,
with his colleagues, has extensively studied this hypothesis in a
nonobese animal model of diabetes (GK rat). They found that a
duodenal-jejunal bypass, which does not result in food restric-
tion or weight loss, leads to improved glucose tolerance in the
diabetic Goto-Kakisaki rat.
In summary, whole-body insulin sensitivity, as measured by
IVGTT, and muscle glucose transport after gastric bypass are
greater than predicted from the weight-matched control group.
We interpret these findings to suggest that the improvement in
insulin sensitivity is not a result of weight loss, but is more likely
related to bypass of the foregut. Based on our results, we believe
that IRS1-Ser312 phosphorylation is a potential cause for the
insulin resistance seen in theweight-matchedandmorbidlyobese
compared with the lean group, and that gastric bypass appears
to result in reduced IRS1-Ser312phosphorylation to levels similar
to lean controls. Finally,we have implicated IKK, anNF-Bpath-
way serine kinase, as a potential culprit responsible for phosphor-
ylating IRS1-Ser312, andwe find that bypass surgerymay indirectly
result in reduced IKK activity in human skeletal muscle.
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